OBI Receives Acceptance of Ten Abstracts at 2026 AACR
Advances Next-Generation ADC Development and Global Partnerships

OBI Pharma (4174.TWO) shared its overall outlook for 2026, noting that its R&D progress is reflected through accelerated international academic and industry engagement. This includes the acceptance of ten research abstracts at the 2026 Annual Meeting of the American Association for Cancer Research (AACR), underscoring the company’s growing momentum in next-generation Antibody-Drug Conjugates (ADCs), alongside continued advancement of its innovative portfolio and research publications.